Skip to main
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

MBX Biosciences is a promising clinical stage biopharmaceutical company with a diverse pipeline of innovative precision peptide therapies for the treatment of endocrine and metabolic disorders. The recent data from their Phase 1 trial of MBX 4291, which showed the potential for monthly dosing and improved tolerability, supports the company's differentiated approach and reinforces its unique value proposition in the obesity field. With a strong management team, a strong cash position, and upcoming milestones expected in the next few years, we believe MBX Biosciences has the potential for long-term success and we maintain a positive outlook on its stock.

Bears say

MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies through their proprietary Precision Endocrine Peptide platform. However, with a negative outlook, the analyst believes that MBX's limited product pipeline and lack of diversified portfolio may hinder its long-term success in the competitive biopharmaceutical market. Furthermore, the company's potential flagship drug, canvuparatide, may face difficulties in gaining approval from regulatory bodies due to its meager 7% average weight loss in Phase 2 trials, which may result in lower sales and revenue projections for the company.

MBX has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 10 analysts, MBX has a Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.